Machavert Pharmaceuticals Will Present at the Annual Meeting of the American Association of Cancer Research (AACR)
Aurora, Colo, March 28, 2019 /PRNewswire/ – Machavert Pharmaceuticals, a preclinical stage pharmaceutical company focused on immuno-oncology and precision medicine cancer therapies, announced today that it will report on the progress of its MP1115 drug candidate at the American Association of Cancer Research (AACR) Annual Meeting 2019 in Atlanta, Georgia. The title of the presentation will be “Characterization of MP1115; a new natural killer cell activator” and will be presented as follows:
Session Category: Clinical Research
Session Title: Immunomodulation by Chemotherapy and Targeted Agents
Session Date and Time: Tuesday Apr 2, 2019 1:00 PM – 5:00 PM
Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 18
Poster Board Number: 5
Permanent Abstract Number: 3949
The data to be presented at AACR focuses on the recent discovery of phospholipids that activate natural killer (NK) cells to trigger anti-tumor cell responses. The phospholipid active pharmaceutical ingredient was formulated as a liposomal nanoparticle, MP1115 that was able to activate NK cells in vitro and in vivo. Preliminary mechanism of action studies revealed downregulation of the CDK8 signaling pathway and pSTAT1-S727. MP1115 showed high tumor bioavailability in vivo and can be combined with payloads to be preferentially delivered to tumors. This was demonstrated in an in vivo orthotopic pancreatic patient derived xenograft tumor model with a fluorescent dye that showed preferential tumor delivery that circumvented liver and other organs.
The efficacy of MP1115 monotherapy as well as MP1115 with other payloads is currently being investigated in multiple in-vivo experiments including human immune system tumor models. The drug candidate is currently entering preclinical IND-enabling studies, a prerequisite for seeking FDA IND approval for human clinical trial entry.
About Machavert Pharmaceuticals
Machavert Pharmaceuticals is a preclinical stage drug development company focused on advanced therapies based on its proprietary bioactive phospholipid platform for the treatment of multiple cancers in hematology and solid tumor oncology. The phospholipid platform is also being combined with other therapeutics such as small molecules for precision medicine and immuno-oncology. Machavert’s core focus is on difficult-to-treat driver mutations and other orphan indications in oncology.
For further information: Neal Goodwin, Chief Science Officer, Machavert Pharmaceuticals, 720.859.4048, firstname.lastname@example.org